glp-1 news today oct 2 2025 trends 2025: real-world data, patient outcomes & future therapies ISPOR 2025: Exploring reasons for

High prevalence of erectile dysfunction in diabetes: a systematic review and meta-analysis of 145 studies

Furthermore, early safety trials that included kidney outcomes as secondary endpoints hinted at potential renal benefits associated with these medication classes

Physiol, 274(3 Pt 2) :H 1054- 1058, 1998

The NAION MCL follows a number of filings by plaintiffs who allege Ozempic and Wegovy caused permanent vision loss and cite recent research linking semaglutide to a significantly increased risk of non-arteritic anterior ischemic optic neuropathy

Raja Sivamani, an Integrative Dermatologist and Adjunct Associate Professor of Dermatology at UC Davis

That was just the most affordable option, she said